Company: IPHYF
Filing Date: 2025-11-28
Form Type: 6-K
Source: 0001628280-25-054231
Chunk: 0

Company: Innate Pharma SA
Filing Date: 2025-11-28
Form: 6-K
Chunk 0
---
### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549 FORM 6-K
<div align='center'>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>

#### Date of report: Friday November 28, 2025

#### Commission File Number: 001-39084

#### Innate Pharma S.A.
<div align='center'>(Translation of registrant's name into English)</div>

#### Innate Pharma S.A.

#### 117 Avenue de Luminy—BP 30191

#### 13009 Marseille, France

#### + 33 (0) 4 30 30 30
<div align='center'>(Address of principal executive office)</div>

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]

### EXHIBIT INDEX

#### Exhibit

#### Description
99.1 Press Release dated November 28, 2025

### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

#### INNATE PHARMA S.A.
Date: November 28, 2025 By: /s/ JONATHAN DICKINSON Name: Jonathan Dickinson

Title: Chief Executive Officer